Literature DB >> 12535830

Long-term outcome in patients with Marfan syndrome: is aortic dissection the only cause of sudden death?

Anji T Yetman1, Renee A Bornemeier, Brian W McCrindle.   

Abstract

OBJECTIVES: We sought to assess outcomes in a series of young patients with Marfan syndrome and to define the prevalence of ventricular arrhythmias in this patient population.
BACKGROUND: While sudden death is a well-recognized outcome in Marfan syndrome, ventricular arrhythmias are not well described.
METHODS: Patients were followed with echocardiography, electrocardiography, and ambulatory electrocardiography. The prevalence and associated factors for ventricular dysrhythmias were defined.
RESULTS: Seventy patients with Marfan syndrome diagnosed at birth to 52 years were followed for a period of up to 24 years. All patients had cardiovascular involvement and were started on medical therapy. No patient died from aortic dissection, while 4% died from arrhythmias. Ventricular arrhythmias were present in 21% and were associated with increased left ventricular size, mitral valve prolapse, and abnormalities of repolarization.
CONCLUSIONS: Cardiac complications are rare in young patients with Marfan syndrome receiving medical therapy and close clinical follow-up. Sudden death still occurs, and appears more common in patients with a dilated left ventricle. Left ventricular dilation may predispose to alterations of repolarization and fatal ventricular arrhythmias.

Entities:  

Mesh:

Year:  2003        PMID: 12535830     DOI: 10.1016/s0735-1097(02)02699-2

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  45 in total

1.  Genetic counseling for the orthodox jewish couple undergoing preimplantation genetic diagnosis.

Authors:  B E David; G A Weitzman; C Hervé; M Fellous
Journal:  J Genet Couns       Date:  2012-04-25       Impact factor: 2.537

2.  Echocardiographic versus histologic findings in Marfan syndrome.

Authors:  Xiaoyan Gu; Yihua He; Zhian Li; Jiancheng Han; Jian Chen; J V Ian Nixon
Journal:  Tex Heart Inst J       Date:  2015-02-01

Review 3.  Initial description of radiofrequency catheter ablation as treatment for atrial flutter in Marfan's syndrome: a case report and literature review.

Authors:  Ahmad Halawa; Vipul Brahmbhatt; Stephen A Fahrig
Journal:  J Interv Card Electrophysiol       Date:  2007-06-28       Impact factor: 1.900

Review 4.  Marfan syndrome: an update of genetics, medical and surgical management.

Authors:  Yskert von Kodolitsch; Peter N Robinson
Journal:  Heart       Date:  2007-06       Impact factor: 5.994

Review 5.  Marfan syndrome. Part 1: pathophysiology and diagnosis.

Authors:  Victoria Cañadas; Isidre Vilacosta; Isidoro Bruna; Valentin Fuster
Journal:  Nat Rev Cardiol       Date:  2010-03-30       Impact factor: 32.419

6.  Heart rate turbulence and deceleration capacity for risk prediction of serious arrhythmic events in Marfan syndrome.

Authors:  Benjamin N Schaeffer; Meike Rybczynski; Sara Sheikhzadeh; Ruken Ö Akbulak; Julia Moser; Mario Jularic; Doreen Schreiber; Anne Daubmann; Stephan Willems; Yskert von Kodolitsch; Boris A Hoffmann
Journal:  Clin Res Cardiol       Date:  2015-06-02       Impact factor: 5.460

7.  Atrial ectopic tachycardia in a patient with marfan syndrome.

Authors:  Jordan D Awerbach; Sammy Khatib; Douglas S Moodie; Christopher S Snyder
Journal:  Ochsner J       Date:  2011

8.  Surgical correction of mitral valve prolapse : a cure for recurrent ventricular tachycardia in Marfan syndrome?

Authors:  Rebecca S Beroukhim; John H Reed; Michael S Schaffer; Anji T Yetman
Journal:  Pediatr Cardiol       Date:  2006-09-30       Impact factor: 1.655

Review 9.  Cardiovascular effects of medications for the treatment of attention-deficit hyperactivity disorder: what is known and how should it influence prescribing in children?

Authors:  Josephine Elia; Victoria L Vetter
Journal:  Paediatr Drugs       Date:  2010-06       Impact factor: 3.022

10.  Marfan syndrome and mitral valve prolapse.

Authors:  Arthur E Weyman; Marielle Scherrer-Crosbie
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.